Where does MSN Laboratories Private Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), MSN Laboratories Private Limited ranks #15,471 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does MSN Laboratories Private Limited hold?

MSN Laboratories Private Limited holds 19 US utility patents granted between 2015 and 2022, spanning 9 technology areas.

What is MSN Laboratories Private Limited's Innovation Score?

MSN Laboratories Private Limited has an Innovation Score of 29.7 out of 100 (32nd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does MSN Laboratories Private Limited focus on?

MSN Laboratories Private Limited's top technology area is C07D (Heterocyclic Compounds) with 17 patents, ranking #514 of 3,165 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is MSN Laboratories Private Limited's patent grant rate increasing or decreasing?

MSN Laboratories Private Limited's recent grant velocity is +11% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for MSN Laboratories Private Limited's patents?

MSN Laboratories Private Limited's patents average 13.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the MSN Laboratories Private Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

MSN Laboratories Private Limited

USPTO PatentsView assignee record - 19 granted patents across 9 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, MSN ranks #15,471 of 49,997 tracked US assignees by granted-patent volume, with 19 patents across 9 technology areas.

#15,471
of 49,997 US assignees by volume: 32nd percentile
by Innovation Score (29.7/100): 13.6
avg claims per patent: +11%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15471 · Foreign Corporation #15,471 · 19 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 19 grants
MID-PACK #15,471/49,997
PHOTO-FINISH Madrigal Pharmaceuti…
CPC-NARROW C07D · 9 areas
INNOV-THIN 29.7/100
CLAIMS-RICH 13.6 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +11% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Madrigal Pharmaceuticals, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How MSN’s 29.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.3 pts (35%) Velocity 0.6 pts (2%) Breadth 10.6 pts (36%) Claim depth 8.1 pts (27%)

Qualcomm Incorporated · highest

85
MSN Laboratories… · this assignee

30
3D Lighting… · lowest

7

What this shows MSN's Innovation Score is 29.7/100 (32nd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for MSN?

Each dot is one of MSN’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). MSN’s own 13.6 claims/patent is at or below the 17.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

MSN vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where MSN's grants concentrate

MSN Laboratories Private Limited is a focused PatentsView assignee: 9 CPC subclasses with 89.5% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2020 (7 grants) versus a trough of 1 in 2016. By volume, MSN sits between Miragen Therapeutics, Inc. and Magswitch Technology, Inc..

MSN's three-year grant acceleration

MSN Laboratories Private Limited shows 1 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Miragen Therapeut…

19
Mocana

19
Moda-innochips

19
Morton Photonics…

19
Murray AND Poole…

19
Madrigal Pharmace…

19
Magik Eye

19
Magswitch Technol…

19
MSN Laboratories… ◀

19

What this shows MSN holds 19 patents at rank #15,451, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near MSN

By rank, the assignees closest to #15,451 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in MSN's primary technology class.

MSN's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 32nd percentile higher than 32% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

MSN Laboratories Private Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	15.8%
2016	1	5.3%
2017	1	5.3%
2018	2	10.5%
2019	2	10.5%
2020	7	36.8%
2021	2	10.5%
2022	1	5.3%

Which technologies does MSN Laboratories Private Limited patent most?

C07D - Heterocyclic Compounds 17

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 10

C07C - Acyclic OR Carbocyclic Compounds 8

B01D - Separation 4

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

C07K - Peptides 2

Y10T - Technical Subjects Covered BY Former US Classification 1

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

MSN Laboratories Private Limited's patent record in context - here's where to go next.

MSN Laboratories Private Limited's lead technology class is C07D (Heterocyclic Compounds), 89.5% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #15,471 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare MSN Laboratories Private Limited against Miragen Therapeutics, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.